Database,
Drug development,
Probability,
Crown Bioscience International,
Clinical trial,
Cancer,
Biomarker,
Gesellschaft mit beschränkter Haftung,
Medicine,
Acquisition,
Therapy,
Pharmaceutical industry HAMBURG, Germany, April 4, 2023 /PRNewswire/ -- After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance. Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
Key Points:
- Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance.
- Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
- "Indivumed's success over the last twenty years has been possible due to our constant focus on highly standardized sample and clinical data collection through a global clinical network.
- Several patents have already been filed and Indivumed Therapeutics proceeds with the identification process for additional targets and biomarkers.
Database,
Drug development,
Probability,
Crown Bioscience International,
Clinical trial,
Cancer,
Biomarker,
Gesellschaft mit beschränkter Haftung,
Medicine,
Acquisition,
Therapy,
Pharmaceutical industry HAMBURG, Germany, April 4, 2023 /PRNewswire/ -- After twenty years as one of the first personalized oncology companies, Indivumed today announced its evolution into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance. Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
Key Points:
- Indivumed Therapeutics emerges as an oncology biotech company focused fully on biomarker and therapeutic target discovery and validation, drug development, and clinical trial performance.
- Indivumed Therapeutics will continue utilizing its global clinical network for biospecimen and clinical data collection to grow its unique multi-omics database using its AI-driven discovery and development platform for novel therapies in oncology.
- "Indivumed's success over the last twenty years has been possible due to our constant focus on highly standardized sample and clinical data collection through a global clinical network.
- Several patents have already been filed and Indivumed Therapeutics proceeds with the identification process for additional targets and biomarkers.
Retrieved on:
Wednesday, January 25, 2023
Research,
Pharmaceutical,
Oncology,
Data Management,
Technology,
Clinical Trials,
Science,
Biotechnology,
Alternative Medicine,
FDA,
Other Science,
Health,
Biomarker,
Agreement,
SOP,
Acquisition,
Crown Bioscience International,
Translation,
PDX,
Partnership,
SPA,
Multimedia,
Doctor of Philosophy,
Collection,
Pharmaceutical industry,
Medical imaging,
Fine chemical,
MD Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH.
Key Points:
- Crown Bioscience , a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH.
- The latter, which is the current IndivuServ business unit of the company, will become a wholly-owned subsidiary of Crown Bioscience and will incorporate all associated laboratory operations and staff located in Hamburg, Germany and Frederick, MD, USA.
- With this partnership Crown Bioscience and Indivumed create a powerhouse for the advancement of precision oncology.
- Further, it fills me with great pride that my hometown Hamburg is emerging as a leading oncology biotech location.”
Retrieved on:
Wednesday, September 7, 2022
Digital,
Neoplasm,
Partnership,
COVID-19,
CEO,
Cancer,
Research,
ESF,
Infection,
ERDF,
REACT,
Data collection,
Founder,
Gesellschaft mit beschränkter Haftung,
Drug development,
Pandemic,
Medical device,
Pharmaceutical industry,
Medical imaging,
EU BERLIN and HAMBURG, Germany, Sept. 7, 2022 /PRNewswire/ -- Indivumed GmbH ("Indivumed") and CELLphenomics GmbH ("CELLphenomics") today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed's AI-driven oncology analytics with CELLphenomics' expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.
Key Points:
- The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.
- "By partnering with CELLphenomics, we will be able to quickly validate therapeutically relevant targets to identify new treatment approaches and accelerate cancer drug development in the future."
- The partnership announcement comes after Indivumed was awarded 4.3 million by the European Union Structural Fund ERDF to accelerate drug development and personalize treatments for cancer.
- Indivumed's analytical platform, nRavel , will identify, characterize, and prioritize potential targets for the selected tumor types.
HAMBURG, Germany, April 5, 2022 /PRNewswire/ -- Indivumed GmbH ("Indivumed") today celebrated the company's 20th anniversary milestone. Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to become a leading innovator in the field of precision oncology.
Key Points:
- HAMBURG, Germany, April 5, 2022 /PRNewswire/ -- Indivumed GmbH ("Indivumed") today celebrated the company's 20th anniversary milestone.
- Founded in Hamburg, Germany on April 5, 2002, Indivumed has rapidly expanded to become a leading innovator in the field of precision oncology.
- At its core, Indivumed was founded as a biobanking company and received recognition from the US National Cancer Institute as being the "golden standard of biobanking."
- "Twenty years ago, the idea for Indivumed came to me when I saw insufficiencies in the datasets available to research individualized cancer therapies.
Retrieved on:
Tuesday, October 26, 2021
Technology,
Research,
Other Technology,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
Science,
Oncology,
Proteomics,
Cancer,
Research,
Technology,
American Society for Mass Spectrometry,
Vaccine,
Biodata,
Workflow,
Partnership,
Annual conferences,
Drug discovery,
Mass spectrometry,
Degenerative disease,
Conference,
Software,
ASMS,
Protein,
Company,
Biomarker,
Solution,
Lung cancer,
Proteome,
Immune system,
Doctor of Philosophy,
AACR,
Society,
Tumor microenvironment,
Pharmaceutical industry,
Medical imaging,
Fine chemical,
Biognosys,
Indivumed,
BIOGNOSYS,
INDIVUMED The partnership is driven by each companys unique capabilities in omics research, with Biognosys bringing industry-leading mass spectrometry-based proteomics technology and solutions, and Indivumed providing high-quality samples and data as well as its multi-omics based AI discovery system, nRavel.
Key Points:
- The partnership is driven by each companys unique capabilities in omics research, with Biognosys bringing industry-leading mass spectrometry-based proteomics technology and solutions, and Indivumed providing high-quality samples and data as well as its multi-omics based AI discovery system, nRavel.
- The initial partnership established in December 2019 focused on enriching Indivumeds IndivuType multi-omics cancer database with proteome-level data from thousands of samples analyzed by Biognosys.
- Since then, Indivumed and Biognosys have successfully collaborated on various clinical research projects and published results from a large-scale study in lung cancer at AACR 2020 , revealing new biomarkers for tumor biology.
- Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: Biognosys HRM technology uniquely addresses key challenges in immunopeptidomics research.
Intelligence,
EMBL,
European Molecular Biology Laboratory,
Therapy,
Top of the Form (quiz show),
CEO,
G protein-coupled receptor,
Precision medicine,
Antibody,
Human,
Technology,
Time,
Cancer,
European,
Colorectal cancer,
Research,
Mouse,
Mab,
Ion,
Disease,
Fine chemical,
Medical device The antibody development and commercialization will be performed by Indivumed's subsidiary, Ix Therapeutics.
Key Points:
- The antibody development and commercialization will be performed by Indivumed's subsidiary, Ix Therapeutics.
- VERAXA Biotech GmbH is a pioneer in microfluidic technology for the screening of antibodies with modulatory function on complex signal proteins like GPCRs or ion channels.
- Besides carrying out service projects, VERAXA is currently also establishing its own proprietary pipeline of therapeutic antibody candidates for further joint development with pharma partners.
- Ix Therapeutics is a subsidiary of Indivumed that was founded in 2021 to develop therapeutic antibodies based on novel and proprietary targets of Indivumed.
HAMBURG, Germany, June 2, 2021 /PRNewswire/ --Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
Key Points:
- HAMBURG, Germany, June 2, 2021 /PRNewswire/ --Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
- Most recently, Merck KGaA, Darmstadt, Germany signed a master collaboration agreement with Indivumed to utilize nRavel's capabilities for the company's drug development activities.
- "The nRavelTM platform puts Indivumed ahead of all other AI-driven drug development platforms.
- "We look forward to partnering with Merck KGaA, Darmstadt, Germany, who recognized our nRavelTM platform as an exciting new solution for drug development."
Most recently, Merck KGaA, Darmstadt, Germany signed a master collaboration agreement with Indivumed to utilize nRavel's capabilities for the company's drug development activities.
Key Points:
- Most recently, Merck KGaA, Darmstadt, Germany signed a master collaboration agreement with Indivumed to utilize nRavel's capabilities for the company's drug development activities.
- "The nRavelTM platform puts Indivumed ahead of all other AI-driven drug development platforms.
- "We look forward to partnering with Merck KGaA, Darmstadt, Germany, who recognized our nRavelTM platform as an exciting new solution for drug development."
- The nRavelTM platform currently includes six toolboxes (immuno-oncology, pathways and signaling, biomarkers, genomics, signatures, clinical analytics), each containing specific applications designed to improve the efficiency and effectiveness of cancer research and drug development projects.
The expansion of IndivuType\'s digital pathology asset and analysis capacity will allow Indivumed and ICGI to combine the cancer phenotype, as defined by the tumor morphology, with the deep molecular multi-omics characterization of the tumor, resulting in better prognostic and diagnostic algorithms which will aid in the personalized treatment of cancer.
Key Points:
- The expansion of IndivuType\'s digital pathology asset and analysis capacity will allow Indivumed and ICGI to combine the cancer phenotype, as defined by the tumor morphology, with the deep molecular multi-omics characterization of the tumor, resulting in better prognostic and diagnostic algorithms which will aid in the personalized treatment of cancer.
- "Our collaboration with the renowned ICGI team at Oslo University Hospital is truly unique in that it will result in the creation of the world\'s first data asset to combine full multi-omics data with clinical and digital pathology data.
- "\nIndivumed will work closely with the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital to leverage artificial intelligence algorithms to deliver a fully automated method of prognosis for colorectal cancer.
- "Working with Indivumed and the tremendous amount of high-quality data contained within the IndivuType discovery solution will help us to better understand the underlying biology of colorectal cancer and more accurately identify potential biomarkers and therapeutic targets.
